SVB Leerink

Protagonist Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference in New York

Retrieved on: 
Wednesday, February 19, 2020
Medical specialties, Blood disorders, Branches of biology, Iron metabolism, Hepatology, Hematopathology, RTT, Peptide hormones, Hepcidin, SVB Leerink, Iron overload, Anemia

NEWARK, Calif., Feb. 19, 2020 /PRNewswire/ --Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a corporate overview at the upcoming the SVB Leerink 9th Annual Global Healthcare Conference in New York.

Key Points: 
  • NEWARK, Calif., Feb. 19, 2020 /PRNewswire/ --Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a corporate overview at the upcoming the SVB Leerink 9th Annual Global Healthcare Conference in New York.
  • PTG-300 is an injectable hepcidin mimetic in development for the potential treatment of iron overload anemia and related rare blood diseases including beta-thalassemia, polycythemia vera and hereditary hemochromatosis.
  • The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the clinical development of PTG-200.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Vericel to Present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020

Retrieved on: 
Wednesday, February 19, 2020
SVB Leerink, Vericel, Trademark, NASDAQ, Companies, Economy of the United States, Finance

CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 9th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 26, 2020 at 2:30pm Eastern Time.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 9th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 26, 2020 at 2:30pm Eastern Time.
  • The company markets two cell therapy products in the United States.
  • Epicel and MACI are registered trademarks of Vericel Corporation.
  • NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation.

Affimed to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, February 19, 2020
SVB Leerink, Oncology, Companies, Economy of the United States

Heidelberg, Germany, February 19, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the SVB Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020 at 10:30 a.m. Eastern Time.

Key Points: 
  • Heidelberg, Germany, February 19, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the SVB Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020 at 10:30 a.m. Eastern Time.
  • A live webcast of the presentation can be accessed under the Investors section of Affimeds website at https://www.affimed.com/investors/webcasts_cp/ and will be available for 30 days following the event.
  • Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer.
  • Affimeds fit-for-purpose ROCK platform allows innate cell engagers to be designed for specific patient populations.

ESCAPE Bio to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Wednesday, February 19, 2020
Health, Genetics, Clinical trials, General Health, Pharmaceutical, Biotechnology, LRRK2, SVB Leerink, Companies, Economy of the United States, ESCAPE Bio, ESB1609, LRRK2 Parkinson’s Disease

ESCAPE Bio, Inc. , a clinical stage company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases, today announced that Julie Anne Smith, Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020.

Key Points: 
  • ESCAPE Bio, Inc. , a clinical stage company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases, today announced that Julie Anne Smith, Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020.
  • Location: Lotte New York Palace in New York, NY
    Ms. Smith will present program and corporate updates.
  • ESCAPE recently initiated a Phase 1 multiple ascending dose study in healthy volunteers with ESB1609 and toxicology studies with their G2019S LRRK2 inhibitor.
  • ESCAPE Bio is a clinical stage, privately held biopharmaceutical company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases.

AlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, February 19, 2020
Infectious diseases, Genetics, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, SVB Leerink, Virus, Immunotherapy, Companies, Viralym-M (ALVR105), AlloVir

AlloVir, a late-clinical stage T-cell immunotherapy company, today announced that its Chief Executive Officer, David Hallal will present at the 9th annual SVB Leerink Global Healthcare Conference on Tuesday February 25th at 2:00 PM ET at the Lotte New York Palace in New York City.

Key Points: 
  • AlloVir, a late-clinical stage T-cell immunotherapy company, today announced that its Chief Executive Officer, David Hallal will present at the 9th annual SVB Leerink Global Healthcare Conference on Tuesday February 25th at 2:00 PM ET at the Lotte New York Palace in New York City.
  • Viralym-M has the potential to fight or prevent a range of severe and life-threatening viral diseases in patients while they are immunocompromised.
  • The companys technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for patients under viral attack.
  • AlloVir is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Axcella to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, February 19, 2020
Health, Other Health, Other Science, Pharmaceutical, Science, Biotechnology, U.S. Securities and Exchange Commission, United States securities law, SVB Leerink, Regulation Fair Disclosure, Finance, Lluís Companys, Economy of the United States, NASDAQ, Financial markets

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the SVB Leerink 9th Annual Global Healthcare Conference in New York City on February 26, 2020 at 9:00 a.m.

Key Points: 
  • Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the SVB Leerink 9th Annual Global Healthcare Conference in New York City on February 26, 2020 at 9:00 a.m.
  • A live audio webcast of the presentation will be available on the Investors & News section of the companys website, www.axcellahealth.com .
  • Axcella uses its website, www.axcellahealth.com , as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
  • Accordingly, investors should monitor such portions of the companys website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Heron Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Tuesday, February 18, 2020
Biotechnology, SVB Leerink, Industries, Companies, Economy of the United States

SAN DIEGO, Feb. 18, 2020 /PRNewswire/ --Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 1:00 p.m.

Key Points: 
  • SAN DIEGO, Feb. 18, 2020 /PRNewswire/ --Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 1:00 p.m.
  • A live webcast of the presentation will be available on the Company's website at www.herontx.com in the Investor Resources section.
  • Heron Therapeutics, Inc.is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs.
  • Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.

Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, February 18, 2020
Finance, Financial markets, Money, Stock market, SVB Leerink, Corporate finance, Stock, Underwriting, NASDAQ

The gross proceeds from the offering were approximately $273.7 million, before deducting underwriting discounts, commissions and other offering expenses payable by Revolution Medicines.

Key Points: 
  • The gross proceeds from the offering were approximately $273.7 million, before deducting underwriting discounts, commissions and other offering expenses payable by Revolution Medicines.
  • Shares of Revolution Medicines common stock began trading on the Nasdaq Global Select Market on February 13, 2020 under the ticker symbol RVMD.
  • All shares in the offering were offered by Revolution Medicines.
  • J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as joint book-running managers for the offering.

Catalent, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Tuesday, February 18, 2020
Biotechnology, Medical devices, Health, Genetics, Pharmaceutical, Life sciences, Articles, Biotechnology, Catalent, Pharmaceutical industry, Biopharmaceutical, SVB Leerink

Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 10:00 a.m.

Key Points: 
  • Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 10:00 a.m.
  • ET on Tuesday, February 25, 2020 in New York City.
  • A live webcast of the presentation will be accessible through the Companys website at http://investor.catalent.com and will be available for replay following the event.
  • Catalent, Inc. (NYSE:CTLT) is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.

Boston Scientific Announces February and March 2020 Conference Schedule

Retrieved on: 
Tuesday, February 18, 2020
SVB Leerink, Finance, BSX, Cowen Inc., Banks, Companies

MARLBOROUGH, Mass., Feb 18, 2020 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming investor conferences.

Key Points: 
  • MARLBOROUGH, Mass., Feb 18, 2020 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming investor conferences.
  • On February 27, 2020, Susie Lisa, vice president, Investor Relations, will participate in a 25-minute question-and-answer session with the host analyst at the SVB Leerink 9th Annual Global Healthcare Conference in New York City.
  • On March 3, 2020, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa will participate in a 30-minute question-and-answer session with the host analyst at Cowen and Company's 40th Annual Health Care Conference in Boston.
  • Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.